Patents by Inventor Anna E. Maciag

Anna E. Maciag has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • K-Ras modulators
    Patent number: 11541044
    Abstract: Provided herein, inter alia, are methods and compounds for inhibiting K-Ras and for treating cancer.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: January 3, 2023
    Assignees: The Regents of the University of California, Leidos Biomedical Research, Inc.
    Inventors: Frank McCormick, Adam R. Renslo, David Turner, Stephan Gysin, Anna E. Maciag, Oleg Chertov
  • K-Ras modulators
    Patent number: 11358940
    Abstract: Provided herein are the K-Ras inhibitors of the formulae: Also provided are compositions comprising thereof for treating cancer.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 14, 2022
    Assignees: The Regents of the University of California, Leidos Biomedical Research, Inc.
    Inventors: Frank McCormick, Adam Renslo, David Turner, Anna E. Maciag, Marcin Dyba, Elizabeth D. Vo, Joseph Saavedra, Vandana Kumari
  • K-RAS MODULATORS
    Publication number: 20210196695
    Abstract: Provided herein, inter alia, are methods and compounds for inhibiting K-Ras and for treating cancer.
    Type: Application
    Filed: October 28, 2020
    Publication date: July 1, 2021
    Inventors: Frank MCCORMICK, Adam R. Renslo, David Turner, Stephan Gysin, Anna E. Maciag, Oleg Chertov
  • K-Ras modulators
    Patent number: 10857140
    Abstract: Provided herein, inter alia, are methods and compounds of formula (I) for inhibiting K-Ras and for treating cancer.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: December 8, 2020
    Assignees: The Regents of the University of California, Leidos Biomedical Research, Inc.
    Inventors: Frank McCormick, Adam R. Renslo, David Turner, Stephan Gysin, Anna E. Maciag, Oleg Chertov
  • K-RAS MODULATORS
    Publication number: 20200247762
    Abstract: Provided herein, inter alia, are methods and compounds for modulating K-Ras treating cancer.
    Type: Application
    Filed: April 20, 2018
    Publication date: August 6, 2020
    Inventors: Frank MCCORMICK, Adam RENSLO, David TURNER, Anna E. MACIAG, Marcin DYBA, Elizabeth D. VO, Joseph SAAVEDRA, Vandana KUMARI
  • K-RAS MODULATORS
    Publication number: 20180289683
    Abstract: Provided herein, inter alia, are methods and compounds for inhibiting K-Ras and for treating cancer.
    Type: Application
    Filed: May 6, 2016
    Publication date: October 11, 2018
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, LEIDOS BIOMEDICAL RESEARCH, INC.
    Inventors: Frank MCCORMICK, Adam R. RENSLO, David TURNER, Stephan GYSIN, Anna E. MACIAG, Oleg CHERTOV
  • Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
    Patent number: 9205091
    Abstract: Disclosed is a method of treating cancer in a patient comprising administering to the patient an effective amount of a diazeniumdiolated (N2O2-containing) compound or a pharmaceutically acceptable salt thereof, wherein the cancer cell has an elevated level of reactive oxygen species (ROS) and/or a decreased level of one or more of PRX1, PRX6, and OGG1, compared to a normal cell of the same tissue or tissue type. An example of a diazeniumdiolated compound is Formula (I), wherein X and Q are defined herein. Also disclosed are diazeniumdiolated compounds, pharmaceutical compositions, and methods of use including enhancing the chemotherapeutic treatment of chemotherapeutic agents and high energy radiation.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: December 8, 2015
    Assignee: The United States of America, as represented by the Secretary Department of Health and Human Services
    Inventors: Anna E. Maciag, Larry K. Keefer, Joseph E. Saavedra, Lucy M. Anderson, Harinath Chakrapani
  • Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
    Patent number: 9168266
    Abstract: Disclosed are hybrid compounds that release both nitric oxide and a moiety that inhibits poly (ADP-ribose) polymerase (PARP), e.g., a compound or a pharmaceutically acceptable salt thereof of formula (I), wherein R1-4 and m-p are as described herein. Also disclosed are pharmaceutical compositions and methods of use including treating cancer and enhancing the chemotherapeutic treatment of chemotherapeutic agents and high energy radiation.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: October 27, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Anna E. Maciag, Larry K. Keefer, Joseph E. Saavedra, Xinhua Ji, Vandana Kumari
  • HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER
    Publication number: 20140315865
    Abstract: Disclosed are hybrid compounds that release both nitric oxide and a moiety that inhibits poly (ADP-ribose) polymerase (PARP), e.g., a compound or a pharmaceutically acceptable salt thereof of formula (I), wherein R1-4 and m-p are as described herein. Also disclosed are pharmaceutical compositions and methods of use including treating cancer and enhancing the chemotherapeutic treatment of chemotherapeutic agents and high energy radiation.
    Type: Application
    Filed: October 18, 2012
    Publication date: October 23, 2014
    Inventors: Anna E. Maciag, Larry K. Keefer, Joseph E. Saavedra, Xinhua Ji, Vandana Kumari
  • DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER
    Publication number: 20120238518
    Abstract: Disclosed is a method of treating cancer in a patient comprising administering to the patient an effective amount of a diazeniumdiolated (N2O2-containing) compound or a pharmaceutically acceptable salt thereof, wherein the cancer cell has an elevated level of reactive oxygen species (ROS) and/or a decreased level of one or more of PRX1, PRX6, and OGG1, compared to a normal cell of the same tissue or tissue type. An example of a diazeniumdiolated compound is Formula (I), wherein X and Q are defined herein. Also disclosed are diazeniumdiolated compounds, pharmaceutical compositions, and methods of use including enhancing the chemotherapeutic treatment of chemotherapeutic agents and high energy radiation.
    Type: Application
    Filed: November 12, 2010
    Publication date: September 20, 2012
    Applicant: The United States of America, as represented by the Secretary, Dept of Health and Human Services
    Inventors: Anna E. Maciag, Larry K. Keefer, Joseph E. Saavedra, Lucy M. Anderson, Harinath Chakrapani